Is the binding of β-amyloid protein to antichymotrypsin in Alzheimer plaques mediated by a β-strand insertion?

Proteins: Structure, Function and Genetics

Volumn 25, Issue 4, 1996, Pages 420-424

  Lukacs, Christine M ^a   Christianson, David W ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

molecular modeling; serpin; sheet rearrangement

Indexed keywords

AMYLOID BETA PROTEIN; CHYMOTRYPSIN INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; GENE INSERTION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION; SEQUENCE HOMOLOGY;

EID: 0029795311     PISSN: 08873585     EISSN: None     Source Type: Journal    
DOI: 10.1002/prot.2     Document Type: Article

References (37)

1. Potempa, J., Korzuss, E., Travis, J. The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J. Biol. Chem. 269:15957-15960, 1994.
2. Schulze, A.J., Huber, R., Bode, W., Engh, R.A. Structural aspects of serpin inhibition. FEBS Lett. 344:117-124, 1994.
3. Travis, J., Salvesen, G.S. Human plasma proteinase inhibitors. Ann. Rev. Biochem. 52:655-709, 1983.
4. 1-antichymotrypsin at 2.7 Å resolution and its comparison with other serpins. J. Mol. Biol. 218:595-606, 1991.
5. Wei, A., Rubin, H., Cooperman, B.S., Christianson, D.W. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop. Nat. Struct. Biol. 1:251-258, 1994.
6. Naidoo, N., Cooperman, B.S., Wang, Z., Liu, X., Rubin, H. Identification of lysines within α1-antichymotrypsin important for DNA binding. J. Biol. Chem. 270:14548-14555, 1995.
7. Tsuda, M., Ohkubo, T., Kamiguchi, H., Suzuki, K., Nakasaki, H., Mitomi, T., Katsunuma, T. Purification, properties, and identification of a serum DNA-binding protein (64DP) and its microheterogeneity. J. Exp. Clin. Med. 7:201-211, 1982.
8. 1-antichymotrypsin. J. Immunol. 146:2388-2393, 1991.
9. Abraham, C.R., Selkoe, D.J., Potter, H. Immunohistochemical identification of the serine protease inhibitor α1-antichymotrypsin inhibitor in the brain amyloid deposits of Alzheimer's disease. Cell 52:487-501, 1988.
10. Potter, H., Nelson, R.B., Das, S., Siman, R., Kayyali, U.S., Dressier, D. The involvement of proteases, protease inhibitors, and an acute phase response in Alzheimer's disease. Ann. NY Acad. Sci. 674:161-173, 1992.
11. Roher, A.E., Lowenson, J.D., Clarke, S., Woods, A.S., Cotter, R.J., Gowing, E., Ball, M.J. β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90:10836-10840, 1993.
12. 1-Antichymotrypsin regulates Alzheimer β-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. U.S.A. 92:2313-2317, 1995.
13. 1-Antichymotrypsin binding to Alzheimer Aβ peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochemistry 61:298-305, 1993.
14. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments. Nature 372:92-94, 1994.
15. 1-antichymotrypsin and β-protein form a stable complex in vitro. In: Alzheimer's Disease: Basic Mechanisms, Diagnosis, and Therapeutic Strategies. Iqbal, K., McLachlan, D.R.C. Winblad, B. Wisniewski, H.M. (eds.). Chichester: John Wiley & Sons, pp. 275-279, 1991.
16. Roberts, E. Alzheimer's disease may begin in the nose and may be caused by aluminosilicates. Neurobiol. Aging 7:561-567, 1986.
17. Matthews, B.W., Craik, C.S., Neurath, H. Can small cyclic peptides have the activity and specificity of proteolytic enzymes? Proc. Natl. Acad. Sci. U.S.A. 91:4103-4105, 1994.
18. Baumann, U., Bode, W., Huber, R., Travis, J., Potempa, J. Crystal structure of cleaved equine leucocyte elastase inhibitor determined at 1.95 A resolution. J. Mol. Biol. 226: 1207-1218, 1992.
19. 1-proteinase inhibitor: Crystal structure analysis of two crystal modifications, molecular model, and preliminary analysis of the implications for function. J. Mol. Biol. 177:531-556, 1984.
20. Mourey, L., Samama, J.-P., Delarue, M., Petitou, M., Choay, J., Moras, D. Crystal structure of cleaved bovine antithrombin III at 3.2 Å resolution. J. Mol. Biol. 232:223-241, 1993.
21. Mottonen, J., Strand, A., Symersky, J., Sweet, R.M., Danley, D.E., Geoghegan, K.F., Gerard, R.D., Goldsmith, E.J. Structural basis of latency in plasminogen activator inhibitor-1. Nature 355:270-273, 1992.
22. Carrell, R.W., Stein, P.E., Fermi, G., Wardell, M.R. Biological implictions of a 3 Å structure of dimeric antithrombin. Structure 2:257-270, 1994.
23. 1 proteinase inhibitor in β-sheet A. Biochemistry 31:7560-7565, 1992.
24. Carrell, R.W., Evans, D.L., Stein, P.E. Mobile reactive centre of serpins and the control of thrombosis. Nature 353: 576-578, 1991.
25. Bruch, M., Weiss, V., Engel, J. Plasma serine proteinase inhibitors (serpins) exhibit major conformational changes and a large increase in conformational stability upon cleavage at their reactive sites. J. Biol. Chem. 263:16626-16630, 1988.
26. Rozemuller, J.M., Abbink, J.J., Kamp, A.M., Stam, P.C., Hack, C.E., Eikelenboom, P. Distribution pattern and functional state of α1-antichymotrypsin in plaques and vascular amyloid in Alzheimer's disease. An immunohistochemical study with monoclonal antibodies against native and inactivated α1-antichymotrypsin. Acta Neuropathol. 82:200-207, 1991.
27. 1-antitrypsin-derived C-terminal peptides. Biol. Chem. Hoppe Seyler 376:415-423, 1995.
28. Fletterick, R.J., McGrath, M.E. Deconvoluting serpins. Nat. Struct. Biol. 1:201-203, 1994.
29. Stein, P.E., Carrell, R.W. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2:96-113, 1995.
30. Sack, J.S. CHAIN: A crystallographic modeling program. J. Mol. Graphics 6:224-225, 1988.
31. Brünger, A.T., Kuriyan, J., Karplus, M. Crystallographic R factor refinement by molecular dynamics. Science 235: 458-460, 1987.
32. Brünger, A.T. X-PLOR Version 3.1 - A system for X-ray crystallography and NMR. New Haven, CT: Yale University Press.
33. Castano, E.M., Ghiso, J., Prelli, F., Gorevic, P.D., Migheli, A., Frangione, B. In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease β-protein. Biochem. Biophys. Res. Comm. 141:782-789, 1986.
34. Kirschner, D.A., Inouye, H., Duffy, L.K., Sinclair, A., Lind, M., Selkoe, D.J. Synthetic peptide homologous to β protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc. Natl. Acad. Sci. U.S.A. 84:6953-6957, 1987.
35. Stein, P.E., Carrell, R.W. What do dysfunctional serpins tell us about molecular mobility and disease? Nat. Struct. Biol. 2:96-113, 1995.
36. Kraulis, P.J. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystellogr. 24:946-950, 1991.
37. Merritt, E.A., Murphy, M.E.P. Raster3D vesion-2.0 - a program for photorealistic molecular graphics. Acta Crystallogr. D50:869-873, 1994.